In this edition: Young women with cancer, warning labels on food and the race to remove 'forever chemicals' from clothing

Younger women are more at-risk for cancer than men. Cancer rates for women in the U.S. have risen over the past half-century, particularly among women under age 65 diagnosed with breast cancer. Men, meanwhile, have experienced a decline in cancer rates compared with prior decades. Changes in smoking habits are partly responsible. Read more.

Largest pharmacy-benefit managers hiked up drug prices. PBMs are supposed to help keep drug costs low for employers and other clients, but the Federal Trade Commission found that the largest ones were overcharging for drugs used to treat cancer, HIV, multiple sclerosis and other diseases. The markups helped PBMs owned by Cigna, CVS Health and UnitedHealth Group reap $7.3 billion from 2017 to 2022. Read more.

The FDA wants to slap warning labels on your food. A new rule proposed Tuesday by the Food and Drug Administration would require food manufacturers to put labels on the front of packages flagging key nutrition information on salt, added sugar and saturated fat. The rule is part of a Biden administration effort to improve American eating habits. Read more.

The race to remove ‘forever chemicals’ from clothing. Bans on the sale of clothing containing chemicals to repel water and prevent stains went into effect in New York and California on Jan. 1. Similar bans are scheduled to roll out in more states next year. The substances persist in the environment for years and have been linked to health problems. Read more.

FDA allows Zyn nicotine pouches to stay on the market. The benefits of America’s most popular flavored nicotine pouch as a safer alternative for adult cigarette smokers outweigh its potential risk to young people, according to the Food and Drug Administration. Read more.

The U.S. bans Red No. 3 from food. The artificial dye has been linked to cancer in animals, from food and ingested drugs. The move will impact thousands of food products on the market in the U.S., including Betty Crocker’s loaded mashed potatoes. Read more.

Johnson & Johnson to acquire Intra-Cellular in $15 billion deal. The pharmaceutical company's decision to acquire mental-illness drug developer Intra-Cellular Therapies is evidence of the industry’s renewed interest in neuroscience bets. The deal would add lumateperone, a pill that treats bipolar depression and schizophrenia, to J&J's portfolio. Read more.

First major healthcare gathering since death of UnitedHealthcare CEO. The JPMorgan conference, held in San Francisco’s Union Square, is among the premier events in healthcare each year, drawing some 20,000 industry professionals, including many executives. This year, safety was a new, and pressing, concern. Read more.

Why food companies want consumers to buy more of everything. To entice inflation-wary consumers to spend more, packaged food and snack company executives are flooding store aisles with new takes on familiar products. Read more.

Trump says world is free-riding on U.S. health spending. The president-elect might bring back efforts to make other countries pay more for drugs. But countries such as the U.K., Germany and France already face stretched healthcare budgets that have sparked political crises. Read more.

This newsletter was compiled by the WSJ’s Health & Science team. Follow us on X @WSJHealth and @WSJScience. Email us by replying to this newsletter.